Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Doerthe Eckert"'
Autor:
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Upadacitinib is an orally administered, selective, Janus kinase inhibitor that is approved for several auto‐immune conditions, such as axial spondyloarthritis, an inflammatory rheumatic disease that includes ankylosing spondylitis (AS) and
Externí odkaz:
https://doaj.org/article/0555cf245c5a4ec08279231b06dd5a7d
Autor:
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, Wen Zhou, Wei Liu, Mohamed-Eslam F. Mohamed
Publikováno v:
Clinical Pharmacokinetics. 62:101-112
Upadacitinib, an oral selective and reversible Janus kinase (JAK) inhibitor, showed favorable efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC). The objective was to characterize upadacitinib pharmacokinetics in UC patie
Autor:
Mohamed Ismail, Eva Doelger, Doerthe Eckert, Alan D. Irvine, Alvina D. Chu, Henrique D. Teixeira, Wei Liu, Ahmed Nader
Publikováno v:
British Journal of Clinical Pharmacology.
Autor:
Sven Stodtmann, Doerthe Eckert, Rujuta Joshi, Silpa Nuthalapati, Christine K. Ratajczak, Rajeev Menon, Sven Mensing, Hao Xiong
Publikováno v:
The Journal of Clinical Pharmacology. 62:1236-1246
Autor:
Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, B. Douglas Smith, Andrew H. Wei, John Hayslip, Dale Miles, Sven Mensing, Sathej Gopalakrishnan, Jiuhong Zha
Publikováno v:
Hematological Oncology. 40:269-279
This study evaluated venetoclax population pharmacokinetics (popPK) in patients with treatment-naïve acute myeloid leukemia and assessed the relationship between venetoclax exposure and clinical response for venetoclax in combination with either a h
Autor:
Rajeev M. Menon, Sreeneeranj Kasichayanula, Rujuta Joshi, Sven Mensing, Hao Xiong, Bruce A. Bach, Doerthe Eckert, Sven Stodtmann, Silpa Nuthalapati
Publikováno v:
Journal of Clinical Pharmacology
Veliparib (ABT‐888) is a poly(ADP‐ribose) polymerase inhibitor in development for the treatment of high‐grade ovarian cancer or BRCA‐mutated breast cancer in combination with carboplatin and paclitaxel. The population pharmacokinetics of veli
Autor:
Mohamed A Badawi, Sheryl Coppola, Doerthe Eckert, Sathej Gopalakrishnan, Eva Doelger, Edyta Dobkowska, Shaji K Kumar, Weize Huang, Rajeev Menon, Ahmed Hamed Salem
Publikováno v:
Blood. 140:4281-4282
Autor:
Sven, Stodtmann, Doerthe, Eckert, Rujuta, Joshi, Silpa, Nuthalapati, Christine K, Ratajczak, Rajeev, Menon, Sven, Mensing, Hao, Xiong
Publikováno v:
Journal of clinical pharmacologyReferences. 62(10)
BRCA-Mutated Advanced Breast Cancer (BROCADE3) is a phase 3 study, evaluating veliparib in combination with carboplatin/paclitaxel with continuation as monotherapy if carboplatin/paclitaxel is discontinued in patients with germline BRCA1/2 mutation-a
Autor:
Chih-Wei Lin, Rajneet K. Oberoi, Sven Mensing, Wei Liu, Hiromitsu Kumada, Koji Kato, Doerthe Eckert, Margaret Burroughs, Kazuaki Chayama, Ahmed Abbas Suleiman
Publikováno v:
The Journal of Clinical Pharmacology. 60:331-339
Glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (Mavyret/Maviret) is an all-oral, pangenotypic, interferon- and ribavirin-free combination regimen approved for the treatment of chronic hepatitis C virus (HCV) infection. The objective of
Autor:
Walid M. Awni, Amit Khatri, Thomas Podsadecki, Doerthe Eckert, Sven Mensing, Akshanth R. Polepally, Sandeep Dutta, Rajeev M. Menon, Shringi Sharma
Publikováno v:
British Journal of Clinical Pharmacology. 83:527-539
Aim To characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir, and dasabuvir) and adjunctive ribavirin and estimate covariate effects in a broad spectrum of subjects wit